1. Home
  2. NUVL vs WH Comparison

NUVL vs WH Comparison

Compare NUVL & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.50

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Logo Wyndham Hotels & Resorts Inc.

WH

Wyndham Hotels & Resorts Inc.

HOLD

Current Price

$87.26

Market Cap

6.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
WH
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
6.4B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
NUVL
WH
Price
$123.50
$87.26
Analyst Decision
Strong Buy
Buy
Analyst Count
16
10
Target Price
$134.75
$94.10
AVG Volume (30 Days)
4.2M
1.3M
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
2.04%
EPS Growth
N/A
N/A
EPS
N/A
0.80
Revenue
N/A
$1,429,000,000.00
Revenue This Year
N/A
$6.86
Revenue Next Year
$1,239.49
$5.83
P/E Ratio
N/A
$107.66
Revenue Growth
N/A
1.49
52 Week Low
$71.14
$69.21
52 Week High
$123.69
$92.69

Technical Indicators

Market Signals
Indicator
NUVL
WH
Relative Strength Index (RSI) 66.42 60.63
Support Level $97.99 $75.75
Resistance Level $123.62 $90.35
Average True Range (ATR) 0.58 2.95
MACD 0.66 0.73
Stochastic Oscillator 99.45 91.90

Price Performance

Historical Comparison
NUVL
WH

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About WH Wyndham Hotels & Resorts Inc.

As of Dec. 31, 2025, Wyndham Hotels & Resorts operates 869,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Ramada is the largest brand, representing around 14% of all rooms, with Days Inn (13%) and Super 8 (10%) the next two largest brands, as of the end of 2025. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represented 58% of total rooms in 2025.

Share on Social Networks: